ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · ESMO Open · 2026-09-16

Bayesian network meta-analysis of five first-line regimens in advanced gastric/GEJ adenocarcinoma: zolbetuximab plus chemotherapy had similar or numerically favourable OS and PFS vs immune checkpoint inhibitors at PD-L1 CPS 1–<10, but numerically worse at CPS ≥10.

Meta-analysis
Shitara et al. Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis
Oncology · Ann Oncol · 2026-08-10

In 5-year follow-up of the phase III CheckMate 648 trial in untreated advanced oesophageal squamous-cell carcinoma with PD-L1 ≥1%, nivolumab plus chemotherapy or ipilimumab improved overall survival vs chemotherapy (both HR 0.62). Grade 3–4 toxicity: 49%, 33% and 37%.

RCTn = 970
Kato et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
Oncology · Br J Cancer · 2026-07-18

In 31 patients with platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma progressing on nivolumab, adding ipilimumab gave 0% response vs 17.6% with docetaxel; median PFS was shorter (1.97 vs 3.66 months), but grade ≥3 events fewer (38.5% vs 68.8%).

RCTn = 31
Grünwald et al. OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
Oncology · Eur J Cancer · 2026-05-27

Exploratory secondary analysis of 127 patients with centrally confirmed advanced papillary RCC in the phase II SUNNIFORECAST trial: 12-month OS was 74.77% with ipilimumab/nivolumab vs 63.44% with standard care (p=0.085, not significant); median OS 24.89 vs 18.88 months.

Secondary analysisn = 127
Ahrens et al. Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Oncology · Eur J Cancer · 2026-05-06

Non-comparative phase II RCT in 141 cisplatin-ineligible patients with R/M HNSCC: 2-year OS was 24.7% with nivolumab plus paclitaxel vs 13.4% with cetuximab, meeting the endpoint, but mortality was higher with nivotax (18% vs 8.3%), mainly respiratory events.

RCTn = 141
Docampo et al. Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study
Oncology · Ann Oncol · 2026-03-03

Final analysis of phase 3 CheckMate 214 (1096 patients, advanced renal cell carcinoma, median follow-up 9.3 years): nivolumab plus ipilimumab vs sunitinib improved OS in intermediate/poor-risk patients (HR 0.69; 108-month OS 30.2% vs 18.7%), with fewer grade 3-4 adverse events.

RCTn = 1,096 patients
Choueiri et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Oncology · J Thorac Oncol · 2026-02-12

Phase 3 trial in metastatic NSCLC with disease control after 6 months of nivolumab-ipilimumab (71 randomised; stopped early): stopping vs continuing gave per-protocol median PFS not reached vs 18.7 months, with fewer grade 3-5 treatment-related adverse events (23.5% vs 54.3%).

RCTn = 71 patients
Zalcman et al. Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial
Oncology · Br J Cancer · 2026-02-06

Secondary analysis of a randomised phase 2 trial in 110 patients with metastatic clear cell renal cell carcinoma: low ipilimumab trough level was linked to worse PFS with nivolumab plus ipilimumab (HR 1.77); nivolumab levels were not; neither predicted death or grade ≥3 TRAEs.

Secondary analysisn = 110
Blanchet et al. Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.